Author

Kristina C. Guillan

Memorial Sloan Kettering Cancer CenterORCID 0009-0007-9668-9859Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Systems Biology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Andrew L. KungiD· 3 shared Daoqi YouiD· 3 shared Filemon S. Dela CruziD· 3 shared Adina GrunniD· 2 shared Andrea CalifanoiD· 2 shared Armaan H. SiddiqueeiD· 2 shared Hanina H. HibshooshiD· 2 shared Peter A. SimsiD· 2 shared

Activity by Year

2023-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersSystems Biology

Andrew L. KungORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyCancer ResearchPeer-reviewedSep 5, 2025

PAX3-FOXO1 drives targetable cell state-dependent metabolic vulnerabilities in rhabdomyosarcoma

Katrina I. Paras, Julia S. Brunner, Jacob A. Boyer…·Lydia W.S. Finley

This study shows that PAX3-FOXO1 drives metabolic vulnerabilities in rhabdomyosarcoma, making these cells sensitive to methotrexate.

4 citations

humanbulk RNA-seq

𝕏 PostBluesky

Systems BiologybioRxivPreprintNov 8, 2023

Identification and Pharmacological Targeting of Treatment-Resistant, Stem-like Breast Cancer Cells for Combination Therapy

Jeremy Worley, Heeju Noh, Daoqi You…·Andrea Califano

The paper identifies treatment-resistant Cancer Stem-Like Cells in breast cancer using single-cell RNA sequencing and validates a drug combination to target them effectively.

1 citation

𝕏 PostBluesky

Systems BiologyCancer DiscoveryPeer-reviewedApr 16, 2023

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

Prabhjot Singh Mundi, Filemon S. Dela Cruz, Adina Grunn…·Andrea Califano

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.

51 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky